Current approach to the biology and treatment of chronic lymphoid malignancies other than CLL
Related Experiment Video
Updated: Aug 17, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
1Academic Department of Haematology, Royal Marsden Hospital, London, England.
Abstract:
A number of discrete disease entities are now well recognised within the lymphoproliferative disorders of B and T lymphocytes. By means of detailed morphologic and immunophenotypic analysis it is possible to distinguish these disorders from chronic lymphocytic leukemia (CLL) and thereby learn about their biology, natural history and response to treatment. We review here the main diagnostic and therapeutic issues of two B-cell disorders: B-prolymphocytic leukemia (B-PLL) and splenic lymphoma with circulating villous lymphocytes (SLVL) and discuss aspects of management and the role of splenectomy and of the nucleoside analog fludarabine in the treatment of B-PLL and SLVL.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Tumor Immunotherapy

